Skip to main content

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Estudi de tolerància perifèrica a la proteïna no estructural NS3 del virus de l'hepatitis C (VHC) per desenvolupar immunoteràpia contra la infecció per VHC per a la prevenció de l'hepatocarcinoma

IP: Juan Ignacio Esteban Mur
Collaborators: Lluis Castells Fusté, Silvia Sauleda Oliveras, Josep Quer Sivila
Funding agency: Fundació La Marató de TV3
Funding: 165000
Reference: TV3/052310
Duration: 01/01/2006 - 31/12/2009

Selección y expansión de linfocitos T CD4+ NS3-específicos de pacientes infectados por Virus de la hepatitis C (VHC). Caracterización del estado de anergia de la infección crónica

IP: -
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Josep Quer Sivila, Juan Ignacio Esteban Mur
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 90750
Reference: SAF2006-03681
Duration: 01/10/2006 - 30/09/2009

Ministerio de Ciencia

Investigación de la tolerancia periférica a NS3 como causa de la persistencia del virus de la hepatitis C (VHC).

IP: Juan Ignacio Esteban Mur
Collaborators: Silvia Sauleda Oliveras, Josep Quer Sivila
Funding agency: Instituto de Salud Carlos III
Funding: 140024
Reference: PI030274
Duration: 01/01/2003 - 28/11/2006

Efecto de la variabilidad genética en la región NS3 del Virus de la hepatitis C (VHC) sobre maduración y presentación de proteínas recombinantes aislado-específicas de células dendríticas autólogas.

IP: -
Collaborators: Silvia Sauleda Oliveras, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Juan Ignacio Esteban Mur
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 164600
Reference: SAF2003-08724
Duration: 15/12/2003 - 15/12/2006

Ministerio de Ciencia

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Jose Fernando Rodríguez Palomares

Jose Fernando Rodríguez Palomares

Main researcher
Cardiovascular Diseases
Read more
Muñoz Vaño, Vicent

Muñoz Vaño, Vicent

Research technician
Nephrology and kidney transplantation
Read more
Català Santarrufina, Alba

Català Santarrufina, Alba

Research technician
Cardiovascular Diseases
Read more
Maria Angeles Jiménez Fuentes

Maria Angeles Jiménez Fuentes

Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.